Prescient Therapeutics announced the appointment of global authority on brain cancer, Donald M. O'Rourke, MD, to its Scientific Advisory Board (SAB). Professor O'Rourke's renowned expertise in glioblastoma multiforme (GBM), the most aggressive form of brain cancer, will be especially valuable in the development of Prescient's OmniCAR GBM program, where the unique features of OmniCAR aim to overcome obstacles that have limited the success of other GBM CAR-T therapies. Professor O'Rourke is a tenured Professor in the department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania (Penn) and the Abramson Cancer Center and holds the John Templeton, Jr., MD Endowed Chair in Neurosurgery. He is Director of the GBM Translational Center of Excellence in Penn's Abramson Cancer Center and has extensively studied therapies for the treatment of GBM. Amongst Professor O'Rourke's many achievements in GBM research is leading the Penn group in the first-in-human clinical trial using CAR-T cells for treatment of recurrent GBM and recently completing a clinical trial for newly diagnosed glioblastoma patients, utilizing a combination of CAR- T cells and PD-1 inhibition.